Compare AIRI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | SNTI |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.4M |
| IPO Year | 2013 | 2021 |
| Metric | AIRI | SNTI |
|---|---|---|
| Price | $2.67 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 25.9K | ★ 194.8K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.39 | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $0.29 |
| 52 Week High | $3.95 | $2.88 |
| Indicator | AIRI | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 29.59 |
| Support Level | $2.55 | N/A |
| Resistance Level | $2.76 | $0.40 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 68.18 | 7.74 |
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).